Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review

Rupak Kanti Biswas; Rupak Roy; Nitin Maksane; Maulik Bhavsar; Ajitabha Sanyal

doi:doi:10.11648/j.ijovs.20210603.13

| Peer-Reviewed

Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review

Rupak Kanti Biswas, Rupak Roy, Nitin Maksane, Maulik Bhavsar, Ajitabha Sanyal

Published in International Journal of Ophthalmology & Visual Science (Volume 6, Issue 3)

Received: 21 June 2021 Accepted: 9 July 2021 Published: 5 August 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The growing incidence of neovascular age-related macular degeneration (nAMD) in India and its debilitating consequences, such as physical, psychological, and emotional stress, are a cause of significant concern. Failing eyesight due to nAMD hinders the ability of patients to perform daily tasks, leading to dependency on others – often resulting in anxiety and depression. Although treatment options such as anti-vascular endothelial growth factors (anti-VEGFs) are readily available, long-term treatment compliance is often compromised. Thus, it is important for health care providers to be aware of the burden associated with nAMD for both patients and caregivers. India, with its large urban and rural population base, faces varied challenges in health care accessibility and affordability. Further, there is a paucity of India-specific studies to ascertain patient and caregiver burden related to nAMD. A deeper understanding of disease awareness and treatment expectations from an Indian perspective may further help clinicians to provide optimum management to patients. The current review provides insights into the quality of life (QoL) and treatment-related burden for patients with nAMD and their caregivers. Further, it emphasizes the need of PAN-India studies to ascertain the patient and caregiver burden related to nAMD, which may assist in devising treatment algorithms and pricing policies suited to the Indian population and enable patients to receive quality eye care.

Published in	International Journal of Ophthalmology & Visual Science (Volume 6, Issue 3)
DOI	10.11648/j.ijovs.20210603.13
Page(s)	164-171
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Wet AMD, nAMD, Caregiver, Treatment Burden, Quality of Life, Patient Perspective, Economic Burden, Indian Perspective

References

[1]	World Health Organisation. Blindness and vision impairment prevention: Priority Eye Diseases. [cited 2020 19 October ]; Available from: http://tdr.who.int/blindness/causes/priority/en/.
[2]	Wong, W. L., et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health, 2014. 2 (2): p. e106-e116.
[3]	Kawasaki, R., et al., The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology, 2010. 117 (5): p. 921-7.
[4]	Parikh, R., et al., A multinational comparison of anti–vascular endothelial growth factor use: The United States, the United Kingdom, and Asia-Pacific. Ophthalmology Retina, 2019. 3 (1): p. 16-26.
[5]	Nirmalan, P. K., et al., Prevalence of vitreoretinal disorders in a rural population of southern India: The Aravind comprehensive eye study. Archives of ophthalmology, 2004. 122 (4): p. 581-586.
[6]	Gupta, S. K., et al., Prevalence of early and late age-related macular degeneration in a rural population in northern India: the INDEYE feasibility study. Invest Ophthalmol Vis Sci, 2007. 48 (3): p. 1007-11.
[7]	Jayashree MP, H. J., Arathi C, Brijesh A Patil and Niveditha RK, Prevalence of age Related Macular Degeneration in A Tertiary Care centre. Journal of Clinical Research and Ophthalmology, 2019.
[8]	Raman, R., et al., The prevalence and risk factors for age-related macular degeneration in rural–urban India, Sankara Nethralaya Rural–Urban Age-related Macular degeneration study, Report No. 1. Eye, 2016. 30 (5): p. 688-697.
[9]	Chakravarthy, U., et al., Progression from Early/Intermediate to Advanced Forms of Age-Related Macular Degeneration in a Large UK Cohort: Rates and Risk Factors. Ophthalmology Retina, 2020. 4 (7): p. 662-672.
[10]	Mathenge, W., Age-related macular degeneration. Community eye health, 2014. 27 (87): p. 49.
[11]	Gohil, R., et al., Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. PloS one, 2015. 10 (6): p. e0129361.
[12]	Bambara, J. K., et al., Family caregiver social problem-solving abilities and adjustment to caring for a relative with vision loss. Investigative ophthalmology & visual science, 2009. 50 (4): p. 1585-1592.
[13]	eyer-Wendl, H. and P. Walter, Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration. Health Economics Review, 2016. 6 (1): p. 37.
[14]	Lim, L. S., et al., Age-related macular degeneration. Lancet, 2012. 379 (9827): p. 1728-38.
[15]	Vaze, A., S. Fraser-Bell, and M. Gillies, Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. Acta ophthalmologica, 2014. 92 (8): p. e697-e698.
[16]	Taylor, D. J., et al., How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ open, 2016. 6 (12): p. e011504.
[17]	Picoto, M., et al., Health and vision related quality of life among patients with choroidal neovascular age related macular degeneration. Revista Brasileira de Oftalmologia, 2015. 74 (4): p. 216-221.
[18]	Klein, B. E., et al., Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. Ophthalmology, 2003. 110 (4): p. 644-50.
[19]	Van Landingham, S. W., et al., Fear of falling in age-related macular degeneration. BMC ophthalmology, 2014. 14 (1): p. 10.
[20]	Müller, S., et al., Treatment of age-related neovascular macular degeneration: the patient’s perspective. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017. 255 (11): p. 2237-2246.
[21]	Banerjee, A., et al., Prevalence of depression and its effect on disability in patients with age-related macular degeneration. Indian journal of ophthalmology, 2008. 56 (6): p. 469.
[22]	Cimarolli, V. R., et al., Anxiety and depression in patients with advanced macular degeneration: current perspectives. Clinical Ophthalmology (Auckland, NZ), 2016. 10: p. 55.
[23]	Varano, M., et al., The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey. Clinical Ophthalmology (Auckland, NZ), 2016. 10: p. 257.
[24]	Azad, R., P. Chandra, and R. Gupta, The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian journal of ophthalmology, 2007. 55 (6): p. 441.
[25]	Kiss, S., et al., Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. J Manag Care Spec Pharm, 2020. 26 (3): p. 253-266.
[26]	Nguyen, Q. D., et al., Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020. 127 (7): p. 963-976.
[27]	Fenwick, E. K., et al., Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2018. 102 (3): p. 377-382.
[28]	Jaffe, D. H., et al., The economic and humanistic burden of patients in receipt of current available therapies for nAMD. Journal of Comparative Effectiveness Research, 2018. 7 (11): p. 1125-1132.
[29]	Bressler, N. M., et al., Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Archives of ophthalmology, 2011. 129 (6): p. 709-717.
[30]	Eleftheriadou, M., et al., Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. American journal of ophthalmology, 2017. 174: p. 160-168.
[31]	Talks, J. S., et al., First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology, 2016. 123 (2): p. 337-343.
[32]	Gillies, M. C., et al., Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology, 2016. 123 (12): p. 2545-2553.
[33]	Zhang, C.-X., et al., Awareness of age-related macular degeneration and its risk factors among beijing residents in China. Chinese medical journal, 2017. 130 (2): p. 155.
[34]	Thapa, R., et al., Population awareness of diabetic eye disease and age related macular degeneration in Nepal: the Bhaktapur Retina Study. BMC Ophthalmology, 2015. 15 (1): p. 188.
[35]	Dandona, R., et al., Awareness of eye diseases in an urban population in southern India. Bull World Health Organ, 2001. 79 (2): p. 96-102.
[36]	Gilbert, C. E., et al., Eye care infrastructure and human resources for managing diabetic retinopathy in India: The India 11-city 9-state study. Indian journal of endocrinology and metabolism, 2016. 20 (Suppl 1): p. S3.
[37]	Misra, V., et al., Models for primary eye care services in India. Indian journal of community medicine: official publication of Indian Association of Preventive & Social Medicine, 2015. 40 (2): p. 79.
[38]	Chellaiyan, V. G., A. Nirupama, and N. Taneja, Telemedicine in India: Where do we stand? Journal of family medicine and primary care, 2019. 8 (6): p. 1872.
[39]	Monés, J., et al., Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica, 2020. 243 (1): p. 1-8.
[40]	Karimi, M. and J. Brazier, Health, health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics, 2016. 34 (7): p. 645-649.
[41]	Péntek, M., et al., Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. BMC geriatrics, 2017. 17 (1): p. 233.
[42]	Spooner, K. L., et al., The burden of neovascular age-related macular degeneration: a patient’s perspective. Clinical Ophthalmology (Auckland, NZ), 2018. 12: p. 2483.
[43]	Prenner, J. L., et al., Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. American journal of ophthalmology, 2015. 160 (4): p. 725-731. e1.
[44]	Boulanger-Scemama, E., et al., Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. Journal francais d'ophtalmologie, 2015. 38 (7): p. 620-627.
[45]	McGrath, L. A. and L. R. Lee, Characteristics of patients who drop out from ranibizumab therapy. The Asia-Pacific Journal of Ophthalmology, 2013. 2 (5): p. 295-299.
[46]	Sudhalkar, A., et al., Retrospective hospital-based analysis of age-related macular degeneration patterns in India: 5-year follow-up. Indian journal of ophthalmology, 2015. 63 (12): p. 899-904.
[47]	Gilbert, C. E., et al., Eye care infrastructure and human resources for managing diabetic retinopathy in India: The India 11-city 9-state study. Indian J Endocrinol Metab, 2016. 20 (Suppl 1): p. S3-s10.
[48]	Gupta IaB, M. International Health Care System Profiles: India. [cited 2020 30th September ]; Available from: https://www.commonwealthfund.org/international-health-policy-center/countries/india.
[49]	Roy, V., U. Gupta, and A. K. Agarwal, Cost of medicines & their affordability in private pharmacies in Delhi (India). Indian J Med Res, 2012. 136 (5): p. 827-35.
[50]	VRSI Market Research Final Report; Available from: https://vrsi.in/wp-content/uploads/2017/07/VRSI-Market-Research.pdf; Accessed on: 19 October 2020. 2017 [cited 2020 19 October]; Available from: https://vrsi.in/wp-content/uploads/2017/07/VRSI-Market-Research.pdf.
[51]	Vukicevic, M., et al., Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. Eye, 2016. 30 (3): p. 413-421.
[52]	Hong, T., et al., Visual impairment and subsequent use of support services among older people: longitudinal findings from the Blue Mountains Eye Study. American Journal of Ophthalmology, 2013. 156 (2): p. 393-399. e1.
[53]	Braich, P. S., et al., Burden and depression in the caregivers of blind patients in India. Ophthalmology, 2012. 119 (2): p. 221-226.
[54]	Economics, D. A. and P. Mitchell, Eyes on the future: A clear outlook on Age-related Macular Degeneration. 2011.
[55]	Gordon, K. D., et al., The cost of vision loss in Canada. 1. Methodology. Canadian journal of ophthalmology, 2011. 46 (4): p. 310-314.

Cite This Article

Plain Text BibTeX RIS

APA Style

Rupak Kanti Biswas, Rupak Roy, Nitin Maksane, Maulik Bhavsar, Ajitabha Sanyal. (2021). Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review. International Journal of Ophthalmology & Visual Science, 6(3), 164-171. https://doi.org/10.11648/j.ijovs.20210603.13

Copy | Download

ACS Style

Rupak Kanti Biswas; Rupak Roy; Nitin Maksane; Maulik Bhavsar; Ajitabha Sanyal. Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review. Int. J. Ophthalmol. Vis. Sci. 2021, 6(3), 164-171. doi: 10.11648/j.ijovs.20210603.13

Copy | Download

AMA Style

Rupak Kanti Biswas, Rupak Roy, Nitin Maksane, Maulik Bhavsar, Ajitabha Sanyal. Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review. Int J Ophthalmol Vis Sci. 2021;6(3):164-171. doi: 10.11648/j.ijovs.20210603.13

Copy | Download

@article{10.11648/j.ijovs.20210603.13,
  author = {Rupak Kanti Biswas and Rupak Roy and Nitin Maksane and Maulik Bhavsar and Ajitabha Sanyal},
  title = {Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review},
  journal = {International Journal of Ophthalmology & Visual Science},
  volume = {6},
  number = {3},
  pages = {164-171},
  doi = {10.11648/j.ijovs.20210603.13},
  url = {https://doi.org/10.11648/j.ijovs.20210603.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20210603.13},
  abstract = {The growing incidence of neovascular age-related macular degeneration (nAMD) in India and its debilitating consequences, such as physical, psychological, and emotional stress, are a cause of significant concern. Failing eyesight due to nAMD hinders the ability of patients to perform daily tasks, leading to dependency on others – often resulting in anxiety and depression. Although treatment options such as anti-vascular endothelial growth factors (anti-VEGFs) are readily available, long-term treatment compliance is often compromised. Thus, it is important for health care providers to be aware of the burden associated with nAMD for both patients and caregivers. India, with its large urban and rural population base, faces varied challenges in health care accessibility and affordability. Further, there is a paucity of India-specific studies to ascertain patient and caregiver burden related to nAMD. A deeper understanding of disease awareness and treatment expectations from an Indian perspective may further help clinicians to provide optimum management to patients. The current review provides insights into the quality of life (QoL) and treatment-related burden for patients with nAMD and their caregivers. Further, it emphasizes the need of PAN-India studies to ascertain the patient and caregiver burden related to nAMD, which may assist in devising treatment algorithms and pricing policies suited to the Indian population and enable patients to receive quality eye care.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review
AU  - Rupak Kanti Biswas
AU  - Rupak Roy
AU  - Nitin Maksane
AU  - Maulik Bhavsar
AU  - Ajitabha Sanyal
Y1  - 2021/08/05
PY  - 2021
N1  - https://doi.org/10.11648/j.ijovs.20210603.13
DO  - 10.11648/j.ijovs.20210603.13
T2  - International Journal of Ophthalmology & Visual Science
JF  - International Journal of Ophthalmology & Visual Science
JO  - International Journal of Ophthalmology & Visual Science
SP  - 164
EP  - 171
PB  - Science Publishing Group
SN  - 2637-3858
UR  - https://doi.org/10.11648/j.ijovs.20210603.13
AB  - The growing incidence of neovascular age-related macular degeneration (nAMD) in India and its debilitating consequences, such as physical, psychological, and emotional stress, are a cause of significant concern. Failing eyesight due to nAMD hinders the ability of patients to perform daily tasks, leading to dependency on others – often resulting in anxiety and depression. Although treatment options such as anti-vascular endothelial growth factors (anti-VEGFs) are readily available, long-term treatment compliance is often compromised. Thus, it is important for health care providers to be aware of the burden associated with nAMD for both patients and caregivers. India, with its large urban and rural population base, faces varied challenges in health care accessibility and affordability. Further, there is a paucity of India-specific studies to ascertain patient and caregiver burden related to nAMD. A deeper understanding of disease awareness and treatment expectations from an Indian perspective may further help clinicians to provide optimum management to patients. The current review provides insights into the quality of life (QoL) and treatment-related burden for patients with nAMD and their caregivers. Further, it emphasizes the need of PAN-India studies to ascertain the patient and caregiver burden related to nAMD, which may assist in devising treatment algorithms and pricing policies suited to the Indian population and enable patients to receive quality eye care.
VL  - 6
IS  - 3
ER  -

Copy | Download

Author Information

Rupak Kanti Biswas

Department of Vitreo – Retina, B. B. Eye Foundation, Kolkata, West Bengal, India
Rupak Roy

Department of Vitreo – Retina, Sankara Nethralaya, Kolkata, West Bengal, India
Nitin Maksane

Novartis Healthcare Pvt. Ltd., Mumbai, Maharashtra, India
Maulik Bhavsar

Novartis Healthcare Pvt. Ltd., Mumbai, Maharashtra, India
Ajitabha Sanyal

Novartis Healthcare Pvt. Ltd., Mumbai, Maharashtra, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Rupak Kanti Biswas, Rupak Roy, Nitin Maksane, Maulik Bhavsar, Ajitabha Sanyal. (2021). Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review. International Journal of Ophthalmology & Visual Science, 6(3), 164-171. https://doi.org/10.11648/j.ijovs.20210603.13

Copy | Download

ACS Style

Rupak Kanti Biswas; Rupak Roy; Nitin Maksane; Maulik Bhavsar; Ajitabha Sanyal. Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review. Int. J. Ophthalmol. Vis. Sci. 2021, 6(3), 164-171. doi: 10.11648/j.ijovs.20210603.13

Copy | Download

AMA Style

Rupak Kanti Biswas, Rupak Roy, Nitin Maksane, Maulik Bhavsar, Ajitabha Sanyal. Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review. Int J Ophthalmol Vis Sci. 2021;6(3):164-171. doi: 10.11648/j.ijovs.20210603.13

Copy | Download

@article{10.11648/j.ijovs.20210603.13,
  author = {Rupak Kanti Biswas and Rupak Roy and Nitin Maksane and Maulik Bhavsar and Ajitabha Sanyal},
  title = {Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review},
  journal = {International Journal of Ophthalmology & Visual Science},
  volume = {6},
  number = {3},
  pages = {164-171},
  doi = {10.11648/j.ijovs.20210603.13},
  url = {https://doi.org/10.11648/j.ijovs.20210603.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20210603.13},
  abstract = {The growing incidence of neovascular age-related macular degeneration (nAMD) in India and its debilitating consequences, such as physical, psychological, and emotional stress, are a cause of significant concern. Failing eyesight due to nAMD hinders the ability of patients to perform daily tasks, leading to dependency on others – often resulting in anxiety and depression. Although treatment options such as anti-vascular endothelial growth factors (anti-VEGFs) are readily available, long-term treatment compliance is often compromised. Thus, it is important for health care providers to be aware of the burden associated with nAMD for both patients and caregivers. India, with its large urban and rural population base, faces varied challenges in health care accessibility and affordability. Further, there is a paucity of India-specific studies to ascertain patient and caregiver burden related to nAMD. A deeper understanding of disease awareness and treatment expectations from an Indian perspective may further help clinicians to provide optimum management to patients. The current review provides insights into the quality of life (QoL) and treatment-related burden for patients with nAMD and their caregivers. Further, it emphasizes the need of PAN-India studies to ascertain the patient and caregiver burden related to nAMD, which may assist in devising treatment algorithms and pricing policies suited to the Indian population and enable patients to receive quality eye care.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Treatment Burden and Quality of Life of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Their Caregivers—A Review
AU  - Rupak Kanti Biswas
AU  - Rupak Roy
AU  - Nitin Maksane
AU  - Maulik Bhavsar
AU  - Ajitabha Sanyal
Y1  - 2021/08/05
PY  - 2021
N1  - https://doi.org/10.11648/j.ijovs.20210603.13
DO  - 10.11648/j.ijovs.20210603.13
T2  - International Journal of Ophthalmology & Visual Science
JF  - International Journal of Ophthalmology & Visual Science
JO  - International Journal of Ophthalmology & Visual Science
SP  - 164
EP  - 171
PB  - Science Publishing Group
SN  - 2637-3858
UR  - https://doi.org/10.11648/j.ijovs.20210603.13
AB  - The growing incidence of neovascular age-related macular degeneration (nAMD) in India and its debilitating consequences, such as physical, psychological, and emotional stress, are a cause of significant concern. Failing eyesight due to nAMD hinders the ability of patients to perform daily tasks, leading to dependency on others – often resulting in anxiety and depression. Although treatment options such as anti-vascular endothelial growth factors (anti-VEGFs) are readily available, long-term treatment compliance is often compromised. Thus, it is important for health care providers to be aware of the burden associated with nAMD for both patients and caregivers. India, with its large urban and rural population base, faces varied challenges in health care accessibility and affordability. Further, there is a paucity of India-specific studies to ascertain patient and caregiver burden related to nAMD. A deeper understanding of disease awareness and treatment expectations from an Indian perspective may further help clinicians to provide optimum management to patients. The current review provides insights into the quality of life (QoL) and treatment-related burden for patients with nAMD and their caregivers. Further, it emphasizes the need of PAN-India studies to ascertain the patient and caregiver burden related to nAMD, which may assist in devising treatment algorithms and pricing policies suited to the Indian population and enable patients to receive quality eye care.
VL  - 6
IS  - 3
ER  -

Copy | Download